Emerging hormonal treatments for menopausal symptoms

Expert Opinion on Emerging Drugs

Volumn 20, Issue 1, 2015, Pages 31-46

  Genazzani, Andrea R ^a   Komm, Barry S ^b   Pickar, James H ^c  

^a UNIVERSITY OF PISA   (Italy)

^b PFIZER INC   (United States)

^c Department of Medicine   (United States)

Author keywords

Conjugated estrogens bazedoxifene; Dehydroepiandrosterone acolbifene; Estrogen receptors; Hormone therapy; Menopause; Ospemifene; TX 001HR; TX 004HR; WC 3011

Indexed keywords

BAZEDOXIFENE; BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN DERIVATIVE; OSPEMIFENE; PAROXETINE; PRASTERONE; PROGESTERONE; RALOXIFENE; TAMOXIFEN; TX 004 HR; UNCLASSIFIED DRUG; WC 3011; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ALZHEIMER DISEASE; AMENORRHEA; AMNESIA; BREAST CANCER; CANCER PREVENTION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DYSPAREUNIA; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HORMONAL THERAPY; HOT FLUSH; HUMAN; LIPID STORAGE; MENOPAUSAL SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; REVIEW; VAGINA ATROPHY; VAGINAL DRYNESS; ADVERSE EFFECTS; ANIMAL; DRUG DESIGN; FEMALE; HOT FLASHES; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL; PROCEDURES;

ANIMALS; DRUG DESIGN; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84923278701     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.986093     Document Type: Review

References (104)

1. Avis NE, Crawford SL, McKinlay SM. Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health 1997; 3: 103-20
2. Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri-and postmenopausal women in the United States. Climacteric 2008; 11: 32-43
3. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008; 23: 1507-13
4. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005; 105: 1063-73
5. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87-94
6. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 25-54
7. Hemminki E, Regushevskaya E, Luoto R, Veerus P. Variability of bothersome menopausal symptoms over time-a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT). BMC Womens Health 2012; 12: 44
8. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005; 3: 47
9. Simon JA, Nappi RE, Kingsberg SA, et al. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause 2014; 21: 137-42
10. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-29
11. The North American Menopause Society. The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause 2012; 19: 257-71
12. Ameye L, Antoine C, Paesmans M, et al. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas 2014. [Epub ahead of print]
13. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012; 120: 595-603
14. Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008; 15: 984-92
15. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243-53
16. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304: 1684-92
17. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13: 476-86
18. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials. JAMA 2013; 310: 1353-68
19. Food and Drug Administration. Guidance for Industry Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommended Prescribing Information for Health Care Providers and Patients Labeling. Available from: http://www.fda. gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135336. pdf [Last accessed 13 October 2014]
20. Food and Drug Administration. Estrogen and estrogen with progestin therapies for postmenopausal women. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318. htm [Last accessed 13 October 2014]
21. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-77
22. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-6
23. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 1999; 20: 253-78
24. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34
25. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
26. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88
27. Christiansen C, Chesnut CH III, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placeboand active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010;11:130
28. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and activecontrolled clinical trial. J Bone Miner Res 2008; 23: 1923-34
29. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005; 105: 1397-404
30. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and activecontrolled study. J Bone Miner Res 2008; 23: 525-35
31. Brisdelle [package insert]. Noven Therapeutics, LLC; Miami, FL: 2013
32. Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013; 20: 1027-35
33. Portman DJ, Kaunitz AM, Kazempour K, et al. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopause 2014; 21: 1082-90
34. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12
35. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
36. Beral V. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 2003; 362: 419-27
37. North American Menopause Society. HT prescriptions: a continued slow decline in 2010 (except for vaginal estrogens). Available from: http://www.menopause. org/publications/clinical-practicematerials/Htstatistics [Last accessed 9 May 2014]
38. Power ML, Anderson BL, Schulkin J. Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause 2009; 16: 500-8
39. American College of Obstetricians and Gynecologists. Committee opinion no. 532: compounded bioidentical menopausal hormone therapy. Available from: http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Compounded-Bioidentical-Menopausal-Hormone-Therapy [Last accessed 21 August 2014]
40. Pickar JH, MacNeil T, Ohleth K. SERMs: progress and future perspectives. Maturitas 2010; 67: 129-38
41. Chang KC, Wang Y, Bodine PV, et al. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010; 118: 117-24
42. Ethun KF, Wood CE, Register TC, et al. Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. Menopause 2012; 19: 1242-52
43. Ethun KF, Wood CE, Cline JM, et al. Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model. Menopause 2013; 20: 777-84
44. Axlund SD, Sartorius CA. Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol 2012; 357: 71-9
45. Liang Y, Benakanakere I, Besch-Williford C, et al. Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause 2010; 17: 1040-7
46. Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 2013; 13: 385-96
47. Rivas MA, Venturutti L, Huang YW, et al. Downregulation of the tumorsuppressor miR-16 via progestinmediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 2012; 14: R77
48. Tkach M, Rosemblit C, Rivas MA, et al. p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocr Relat Cancer 2013; 20: 197-212
49. Osphena [package insert]. Shionogi, Inc; Florham Park, NJ: 2013
50. European Medicines Agency. Applications for new human medicines under evaluation by the committee for medicinal products for human use. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/Report/2014/07/WC500169655.pdf [Last accessed 10 July 2014]
51. Duavee [package insert]. Wyeth Pharmaceuticals, Inc., A subsidiary of Pfizer, Inc; Philadelphia, PA: 2013
52. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006 (4): CD001500
53. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20: 888-902
54. TherapeuticsMD. NYSE MKT: TXMD Corporate Overview. Available from: http://www.therapeuticsmd.com/presentations.aspx [Last accessed 13 May 2014]
55. ClinicalTrials.gov. Safety & efficacy WC3011 in the treatment of vulvovaginal atrophy in postmenopausal women (VENUS) NCT01400776. Available from: http://www.clinicaltrials. gov/ct2/show/NCT01400776? term=vulvovaginal+atrophy&rank=1 [Last accessed 9 May 2014]
56. ClinicalTrials.gov. Evaluate long-term safety and efficacy WC3011 NCT01455597. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01455597? term=vulvovaginal+atrophy&rank=2 [Last accessed 9 May 2014]
57. ClinicalTrials.gov. Study to evaluate safety & efficacy of WC3011 in postmenopausal women with dyspareunia. NCT01845649. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01845649? term=vulvovaginal+atrophy&rank=8 [Last accessed 9 May 2014]
58. ClinicalTrials.globe24g.com. Evaluate long-term safety and efficacy WC3011. NCT01455597 Available from: http://clinicaltrials.globe24h.com/0/0/symptoms-and-general-pathology/a/atrophy/2011/10/17/nct01455597-evaluate-long-term-safety-and-efficacywc3011-warner-chilcott.shtml [Last accessed 9 May 2014]
59. ClinicalTrials.gov. Multicenter study to evaluate safety and efficacy of WC3011 in postmenopausal women. NCT01816139 Available from: http://clinicaltrials.gov/ct2/show/NCT01816139 [Last accessed 9 May 2014]
60. Business Wire. Therapeutics MD reports positive results of rabbit irritation study for its estradiol vaginal capsule VagiCap (TX 004-HR) for treatment of vulvar vaginal atrophy (VVA) [press release]. Available from: http://www. businesswire.com/news/home/20140407005470/en/TherapeuticsMDReports-Positive-Results-Rabbit-Irritation-Study#.U3OtSPldX9Z [Last accessed 13 May 2014]
61. Therapeutics MD. Therapeutics MD reports positive PK study results for its estradiol vaginal capsule VagiCap (TX 12-004-HR) for treatment of vulvar vaginal atrophy (VVA) [press release]. Available from: http://www. therapeuticsmd.com/pressreleases.aspx [Last accessed 13 May 2014]
62. PBR Contract Research & Services Clinical Trial. TherapeuticsMD reports positive PK study results for vulvar vaginal atrophy drug [press release]. Available from: http://clinicaltrials. pharmaceutical-business-review.com/news/therapeuticsmd-reports-positive-pkstudy-results-for-vulvar-vaginal-atrophydrug-290114-4167592 [Last accessed 9 May 2014]
63. Food and Drug Administration. Compounded menopausal hormone therapy questions and answers. Available from: http://www.fda.gov/drugs/guidancecomplianceregulatory information/pharmacycompounding/ucm183088.htm [Last accessed 14 May 2014]
64. American College of Obstetricians and Gynecologists. Practice bulletin no. 141: management of menopausal symptoms. Obstet Gynecol 2014; 123: 202-16
65. Business Wire. Therapeutics MD to present the design of its REPLENISH trial at the International Menopause Society's 14th World Congress [press release]. Available from: http://www. businesswire.com/news/home/20140501006446/en/TherapeuticsMDPresent-Design-REPLENISH-Trial-International-Menopause#. U3OxOPldX9Z [Last accessed 12 May 2014]
66. Pickar JH, Bon C, Amadio JM, Bernick B. Pharmacokinetics of the first combination 15-estradiol/progesterone capsule in clinical development for hormone therapy [abstract P-81]. Presented at: annual Meeting of the North American Menopause Society; 9-12 October 2013; Grapevine, TX
67. ClinicalTrials.gov. A safety and efficacy study of the combination estradiol and progesterone to treat vasomotor symptoms (REPLENISH) NCT01942668. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01942668? term=REPLENISH&rank=1 [Last accessed 21 April 2014]
68. ClinicalTrials.gov. Dehydroepiandrosterone (DHEA) + acolbifene against vasomotor symptoms (hot flushes) in postmenopausal women. NCT01452373. Available from: http://www.clinicaltrials. gov/ct2/show/NCT01452373? term=acolbifene&rank=1 [Last accessed 9 May 2014]
69. Femivia. Endoceutics. Available from: http://www.endoceutics.com/ourproducts/femivia8482/?no-cache=1&sword-list[0]=femivia [Last accessed 12 May 2014]
70. Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res 2010; 182: 97-148
71. Goss PE, Qi S, Cheung AM, et al. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogeninduced uterine hypertrophy in ovariectomized rats. J Steroid Biochem Mol Biol 2004; 92: 79-87
72. Berger L, El-Alfy M, Martel C, Labrie F. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol 2005; 96: 201-15
73. Pelletier G, Ouellet J, Martel C, Labrie F. Androgenic action of dehydroepiandrosterone (DHEA) on nerve density in the ovariectomized rat vagina. J Sex Med 2013; 10: 1908-14
74. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17: 480-6
75. Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20: 623-30
76. Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014; 17: 173-82
77. Simon JA, Lin VH, Radovich C, Bachmann GA. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013; 20: 418-27
78. Kharode Y, Bodine PV, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008; 149: 6084-91
79. Liu S, Han SJ, Smith CL. Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes. Mol Pharmacol 2013; 83: 1066-77
80. Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 2011; 80: 610-20
81. Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 2011; 80: 610-20
82. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009; 92: 1025-38
83. Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009; 92: 1039-44
84. Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009; 92: 1045-52
85. Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause 2013; 20: 138-45
86. Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissueselective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009; 16: 1116-24
87. Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissueselective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009; 16: 1116-24
88. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010; 13: 132-40
89. Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013; 16: 338-46
90. Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 2013; 121: 959-68
91. Pinkerton JV, Pan K, Abraham L, et al. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. Menopause 2014; 21: 252-9
92. Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014; 99: E189-98
93. Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014; 99: E189-98
94. Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014; 99: E189-98
95. LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010; 102: 1706-15
96. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006; 13: 377-86
97. Stovall DW, Utian WH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007; 14: 510-17
98. Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med 2007; 52: 93-6
99. Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009; 150: 1897-903
100. Pluchino N, Drakopoulos P, Bianchi-Demicheli F, et al. Neurobiology of DHEA and effects on sexuality, mood and cognition. J Steroid Biochem Mol Biol 2014. [Epub ahead of print]
101. Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011; 14: 661-8
102. Huang P, Chandra V, Rastinejad F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu Rev Physiol 2010; 72: 247-72
103. Berrodin TJ, Chang KC, Komm BS, et al. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifeneconjugated estrogens combination. Mol Endocrinol 2009; 23: 74-85
104. Kulak J Jr, Fischer C, Komm B, Taylor HS. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology 2011; 152: 3226-32